[go: up one dir, main page]

AR046774A1 - LIOFILIZED FORMULATION OF ANTIBODY CONJUGATES - Google Patents

LIOFILIZED FORMULATION OF ANTIBODY CONJUGATES

Info

Publication number
AR046774A1
AR046774A1 ARP040104838A ARP040104838A AR046774A1 AR 046774 A1 AR046774 A1 AR 046774A1 AR P040104838 A ARP040104838 A AR P040104838A AR P040104838 A ARP040104838 A AR P040104838A AR 046774 A1 AR046774 A1 AR 046774A1
Authority
AR
Argentina
Prior art keywords
liofilized
formulation
antibody conjugates
antibody
complexes
Prior art date
Application number
ARP040104838A
Other languages
Spanish (es)
Inventor
Patrick Garidel
Nicole Denkinger
Christian Berger
Stefan Bassarab
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2003161598 external-priority patent/DE10361598A1/en
Priority claimed from DE102004014783A external-priority patent/DE102004014783A1/en
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of AR046774A1 publication Critical patent/AR046774A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composiciones farmacéuticas liofilizadas de anticuerpos, preferiblemente de anticuerpos que están conjugados con una molécula de efector. En particular, se refiere a formulaciones liofilizadas estables de complejos de anticuerpo-DM1. Además, se refiere a procedimientos para la liofilización de complejos de anticuerpo-DM1. Uso de dicha composición para el tratamiento de una enfermedad cancerigena.Lyophilized pharmaceutical compositions of antibodies, preferably antibodies that are conjugated to an effector molecule. In particular, it refers to stable lyophilized formulations of antibody-DM1 complexes. In addition, it refers to procedures for lyophilization of antibody-DM1 complexes. Use of said composition for the treatment of a cancer disease.

ARP040104838A 2003-12-24 2004-12-22 LIOFILIZED FORMULATION OF ANTIBODY CONJUGATES AR046774A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2003161598 DE10361598A1 (en) 2003-12-24 2003-12-24 The freeze-dried pharmaceutical composition as the conjugate of an antibody with a mytansinoid, for the treatment of cancers, is set to a given concentration and pH value before freeze drying
DE102004014783A DE102004014783A1 (en) 2004-03-24 2004-03-24 The freeze-dried pharmaceutical composition as the conjugate of an antibody with a mytansinoid, for the treatment of cancers, is set to a given concentration and pH value before freeze drying

Publications (1)

Publication Number Publication Date
AR046774A1 true AR046774A1 (en) 2005-12-21

Family

ID=34751258

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104838A AR046774A1 (en) 2003-12-24 2004-12-22 LIOFILIZED FORMULATION OF ANTIBODY CONJUGATES

Country Status (3)

Country Link
AR (1) AR046774A1 (en)
TW (1) TW200533375A (en)
WO (1) WO2005065709A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361599A1 (en) * 2003-12-24 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Liquid formulation of antibody conjugates
JP2009503105A (en) 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド Immune complex preparation
GB201220889D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating metastasizing cancers
GB201220891D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating breast cancers
GB201220901D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating pancreatic cancer
HK1220698A1 (en) 2013-03-13 2017-05-12 Seattle Genetics, Inc. Cyclodextrin and antibody-drug conjugate formulations
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
KR102735988B1 (en) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 therapeutic antibody preparations
CN116479088B (en) * 2022-11-15 2024-11-05 江苏默乐生物科技股份有限公司 Reagent combination, kit, method and application for freeze-drying preservation of biological reagent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE10361599A1 (en) * 2003-12-24 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Liquid formulation of antibody conjugates

Also Published As

Publication number Publication date
WO2005065709A2 (en) 2005-07-21
WO2005065709A3 (en) 2006-08-24
TW200533375A (en) 2005-10-16

Similar Documents

Publication Publication Date Title
WO2019094395A3 (en) Hydrophilic linkers for antibody drug conjugates
CA2910494C (en) Insulin-oligomer conjugates, formulations and uses thereof
BRPI0516284A (en) cysteine-constructed antibody, method of selecting antibodies, drug-antibody conjugated compounds, pharmaceutical composition, method for killing or inhibiting tumor cell proliferation, methods of inhibiting cell proliferation and tumor cell growth, manufactured article and method to produce a compound
EA200301159A1 (en) Cytotoxic Immunoconjugates Antibodies to CD44
DE602004027888D1 (en) ANTI-CD70 ANTIBODY MEDICAMENT CONJUGATES AND THEIR
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
CY1112682T1 (en) Active IL-18 Protein Conjugates and their Medical Uses
ECSP077261A (en) HER2 ANTIBODY COMPOSITION
PE20110065A1 (en) COMPOSITIONS AND METHODS FOR PREPARING IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS SEROTYPES 5 AND 8 CAPSULAR POLYSACCHARIDE CONJUGATE
BR0116587A (en) Use of an erythropoietin, pharmaceutical composition, methods for protecting, maintaining or enhancing the viability of a cell, tissue or organ isolated from a mammalian body, to facilitate trancitosis of a molecule through a cellular endothelial barrier in a mammal, composition for transport. a molecule via trancitose through a cellular endothelial barrier, and, composition
AR069747A1 (en) ANTI-B7H4 MONOCLONAL ANTIBODY CONJUGATE - PHARMACO AND METHODS OF USE
CY1119968T1 (en) COMPOSITIONS OF INNOVATIVE COSMETIC AND / OR PHARMACEUTICAL PRODUCTS AND THEIR USES
BRPI0519232A2 (en) saccharide conjugate vaccines
EA200802170A1 (en) LYOPHILIZED COMPOSITION OF THERAPEUTIC PEPTIDE ANTIBODY
BRPI0309868B1 (en) methods of preparing a lower conjugated fraction composition
MX2008009357A (en) A solid lyophilized taxane composition, a method for preparing said solid composition, a pharmaceutical formulation and a kit for said formulation.
BRPI0409133A (en) pharmaceutical formulations containing methylnaltrexone
PE20240067A1 (en) ADJUVANT COMPOSITION OF NANOEMULSIONS FOR PNEUMOCOCCAL CONJUGATE VACCINES
WO2017180789A3 (en) Methods of treatment using chlorotoxin conjugates
CL2007001648A1 (en) Leptomycin derived compound; conjugate comprising cell binding agent bound to one or more of said derivatives; pharmaceutical compositions comprising said derivative or conjugate; useful in the treatment of cancer; process of preparing a compound or a conjugate of a leptomycin derivative.
AR078470A1 (en) ANTIBODIES THAT SPECIFICALLY JOIN THE EPHA2 RECEIVER
CL2008003537A1 (en) 2-aminopyrimidine derived compounds, h4 receptor antagonists; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound in the treatment of an allergic, immunological or inflammatory disease or pain.
GT200600001A (en) USE OF CYANINE COLORS FOR THE DIAGNOSIS OF PROLIFERATIVE DISEASES
AR046774A1 (en) LIOFILIZED FORMULATION OF ANTIBODY CONJUGATES
AR117652A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING CONJUGATES OF ANTI-191P4D12 ANTIBODY AND DRUG AND METHODS OF USING THEM

Legal Events

Date Code Title Description
FB Suspension of granting procedure